P. Bérard

EURADOS-IDEAS GUIDELINES (VERSION 2) FOR THE ESTIMATION OF COMMITTED DOSES FROM INCORPORATION MONITORING DATA.

Dose assessment after intakes of radionuclides requires application of biokinetic and dosimetric models and assumptions about factors influencing the final result. In 2006, a document giving guidance for such assessment was published, commonly referred to as the IDEAS Guidelines. Following its publication, a working group within the European networks CONRAD and EURADOS was established to improve and update the IDEAS Guidelines. This work resulted in Version 2 of the IDEAS Guidelines, which was published in 2013 in the form of a EURADOS report. The general structure of the original document was maintained; however, new procedures were included, e.g. the direct dose assessment method for (3)H or special procedure for wound cases applying the NCRP wound model. In addition, information was updated and expanded, e.g. data on dietary excretion of U, Th, Ra and Po for urine and faeces or typical and achievable values for detection limits for different bioassay measurement techniques.

Biokinetic modelling of DTPA decorporation therapy: the CONRAD approach

Administration of diethylene triamine pentaacetic acid (DTPA) can enhance the urinary excretion rate of plutonium (Pu) for several days, but most of this Pu decorporation occurs on the first day after treatment. The development of a biokinetic model describing the mechanisms of decorporation of actinides by administration of DTPA was initiated as a task of the coordinated network for radiation dosimetry project. The modelling process was started by using the systemic biokinetic model for Pu from Leggett et al. and the biokinetic model for DTPA compounds of International Commission on Radiation Protection Publication 53. The chelation of Pu and DTPA to Pu-DTPA was treated explicitly and is assumed to follow a second-order process. It was assumed that the chelation takes place in the blood and in the rapid turnover soft tissues compartments of the Pu model, and that Pu-DTPA behaves in the same way as administered DTPA. First applications of this draft model showed that the height of the peak of urinary excretion after administration of DTPA was determined by the chelation rate. However, repetitions of DTPA administration shortly after the first one showed no effect in the application of the draft model in contrast to data from real cases. The present draft model is thus not yet realistic. Therefore several questions still have to be answered, notably about where the Pu-DTPA complexes are formed, which biological ligands of Pu are dissociated, if Pu-DTPA is stable and if the biokinetics of Pu-DTPA excretion is similar to that of DTPA. Further detailed studies of human contamination cases and experimental data about Pu-DTPA kinetics will be needed in order to address these issues. The work will now be continued within a working group of EURADOS.

Assessment of Iodine in the Diet of People Living Around a Nuclear Reprocessing Plant: Dose-Related Consequences of an Intake of 129I

It is important that in radioiodine dosimetry for low levels of daily intake, allowance must be made for the normal daily intake of stable iodine. This intake varies from one region to another, and variations are observed from one person to the next within a region, depending on eating habits. Measuring iodine in the urine over 24 hours can indirectly assess these variations. Analysis of the total iodine in the urine was carried out for 69 French people living in a temperate maritime region or in mainland France. This study justifies individual assessment of the coefficient of iodine transfer to the thyroid by means of this survey based on the urinary iodine analysis. The consequences for man of the release of 129I around a nuclear reprocessing plant were analyzed by applying the methodology published previously by the authors. A software program based on the iodine biokinetic model recommended by the ICRP was used to calculate the daily urine excretion of 129I for five different diets of total iodide in a ratio of 10-4 for 129I/127I. This model makes it possible to set a practical detection limit of 20 mBq (0.003 µg). This approach is important from a practical point of view for health physicists involved in routine monitoring of workers in the nuclear field and members of the public exposed to radioiodine released into the environment.

DOSIMETRIC MANAGEMENT DURING A CRITICALITY ACCIDENT

A working group from health occupational and clinical biochemistry services on French sites has issued essential data sheets on the guidelines to follow in managing the victims of a criticality accident. Since the priority of the medical management after a criticality accident is to assess the dose and the distribution of dose, some dosimetric investigations have been selected in order to provide a prompt response and to anticipate the final dose reconstruction. Comparison exercises between clinical biochemistry laboratories on French sites were carried out to confirm that each laboratory maintained the required operational methods for hair treatment and the appropriate equipment for 32P activity in hair and 24Na activity in blood measurements, and to demonstrate its ability to rapidly provide neutron dose estimates after a criticality accident. As a result, a relation has been assessed to estimate the dose and the distribution of dose according to the neutron spectrum following a criticality accident.

MADOR: a new tool to calculate decrease of effective doses in human after DTPA therapy

Abstract models have been developed to describe dissolution of Pu/Am/Cm after internal contamination by inhalation or wound, chelation of actinides by diethylene triamine penta acetic acid (DTPA) in different retention compartments and excretion of actinide-DTPA complexes. After coupling these models with those currently used for dose calculation, the modelling approach was assessed by fitting human data available in IDEAS database. Good fits were obtained for most studied cases, but further experimental studies are needed to validate some modelling hypotheses as well as the range of parameter values. From these first results, radioprotection tools are being developed: MAnagement of DOse Reduction after DTPA therapy.

Intercalibration of French Lung Monitoring Systems for Actinide Measurements

French laboratories involved in lung measurements of actinides have decided to initiate an intercalibration circuit as an easier intermediate step of quality assurance, by using a well-characterised phantom to make a detailed comparison of the measuring procedures used by the centres. Thirteen facilities from nine laboratories took part in this intercalibration. The first phase has been completed. The response of instrumentation and detectors with respect to metrological parameters and measurements on Livermore phantoms is here presented. Current efforts are being directed toward the redaction of consistent procedures: this is also discussed.